Abstract
Current therapeutic strategies to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) use a combination of drugs targeted at the viral reverse transcriptase, protease and integrase enzymes. The clinical advantages of this combination therapy are considerable, although the emergence of drug-resistant viral strains still presents a challenge. Import of the HIV-1 viral pre-integration complex (PIC) into the nucleus is a vital step in the process of viral replication in non-dividing cells (such as terminally differentiated macrophages). The interaction between the HIV-1 accessory protein, Vpr, and the cellular protein, importin-α, is critical for nuclear import of the PIC. Targeting the protein-protein interactions involved in the regulation of HIV-1 replication might be one way to combat the continued emergence of drug-resistant HIV-1 mutants. In this review, the current status of AIDS therapy, the mechanisms involved in the nuclear import of the PIC and the discovery of a new small molecular inhibitor of HIV-1 replication are discussed.
Keywords: HIV-1 Vpr, nuclear import, pre-integration complex (PIC), importin (Imp)- α, anti-HIV-1 therapy, small molecule inhibitor
Current Chemical Biology
Title: Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Volume: 4 Issue: 3
Author(s): Guangai Xue and Yoko Aida
Affiliation:
Keywords: HIV-1 Vpr, nuclear import, pre-integration complex (PIC), importin (Imp)- α, anti-HIV-1 therapy, small molecule inhibitor
Abstract: Current therapeutic strategies to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) use a combination of drugs targeted at the viral reverse transcriptase, protease and integrase enzymes. The clinical advantages of this combination therapy are considerable, although the emergence of drug-resistant viral strains still presents a challenge. Import of the HIV-1 viral pre-integration complex (PIC) into the nucleus is a vital step in the process of viral replication in non-dividing cells (such as terminally differentiated macrophages). The interaction between the HIV-1 accessory protein, Vpr, and the cellular protein, importin-α, is critical for nuclear import of the PIC. Targeting the protein-protein interactions involved in the regulation of HIV-1 replication might be one way to combat the continued emergence of drug-resistant HIV-1 mutants. In this review, the current status of AIDS therapy, the mechanisms involved in the nuclear import of the PIC and the discovery of a new small molecular inhibitor of HIV-1 replication are discussed.
Export Options
About this article
Cite this article as:
Xue Guangai and Aida Yoko, Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug, Current Chemical Biology 2010; 4 (3) . https://dx.doi.org/10.2174/2212796811004030188
DOI https://dx.doi.org/10.2174/2212796811004030188 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Molecular Mechanisms of Angiotensin II Type 1 and 2 Receptors
Current Pharmaceutical Design Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Accuracy of a Topical PET/CT Scanner on SUV Measurements of Small Volumes SUV
Current Medical Imaging Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Subject Index To Volume 7
Current Drug Targets The Use of Adenoviral Vectors for Genetic Manipulation and Analysis of Primitive Hematopoietic Cells
Current Gene Therapy Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry